文献速递头颈甲状腺与浅表介入US

局部复发性甲状腺乳头状癌射频消融治疗的十年结局

Ten-Year Outcomes of Radiofrequency Ablation for Locally Recurrent Papillary Thyroid Cancer.
PubMed 文献 · Korean J Radiol · 2024-01-01

回顾性分析39例共61个局部复发性甲状腺乳头状癌病灶接受超声引导下射频消融的资料,随访7至180个月(中位133个月),3年、5年、10年无复发生存率分别为86.8%、75.5%、60.6%;随访超过10年的24例37个病灶体积缩小率达99.9%,肿瘤完全消失率91.9%,血清甲状腺球蛋白显著下降,未观察到危及生命或迟发并发症。

要点

  • 超声引导下射频消融可作为局部复发性甲状腺乳头状癌局部控制的可选方案。
  • 39例患者3年、5年、10年无复发生存率分别为86.8%、75.5%、60.6%。
  • 随访超过10年的24例中肿瘤完全消失率为91.9%,体积缩小率达99.9%。

核心结论

  • 整个随访期间无复发生存率较高,疗效和安全性持续超过10年,支持超声引导下射频消融作为局部复发性甲状腺乳头状癌局部控制的有价值选择。

研究设计与样本

  • 回顾性分析2008年9月至2012年4月间连续39例(14男、25女,平均年龄52.8±16.7岁,范围21-92岁)共61个局部复发性甲状腺乳头状癌病灶,接受超声引导下以治愈为目的的射频消融;另对24例37个复发病灶且随访至少10年的亚组单独分析。

诊断标准与关键数值

  • 39例患者3年、5年、10年无复发生存率分别为86.8%、75.5%、60.6%;随访超过10年的24例37个复发病灶体积缩小率为99.9%(范围96%-100%),肿瘤完全消失率为91.9%;24例中14例(58.3%)末次随访时甲状腺球蛋白低于0.08 mIU/L。

临床应用与阅片要点

  • 随访期间采用超声评估病灶大小变化,并在射频消融后1、3、6、12个月检测甲状腺球蛋白水平,此后每6-12个月随访一次;24例随访超过10年患者平均血清甲状腺球蛋白由消融前2.66±86.5 mIU/L降至末次随访0.43±0.73 mIU/L(P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: This study investigates the long-term efficacy and safety of ultrasound (US)-guided radiofrequency ablation (RFA) for treating locally recurrent papillary thyroid cancer (PTC).

MATERIALS AND METHODS: We retrospectively analyzed 39 consecutive patients with 61 locally recurrent PTCs (14 males, 25 females; mean ± standard deviation age, 52.8 ± 16.7 years; range 21-92 years) who underwent US-guided RFA with curative intent between September 2008 and April 2012. A subgroup of 24 patients with 37 recurrent PTCs who had a follow-up of at least 10 years were analyzed separately. All patients were followed for changes in lesion size on US and thyroglobulin (Tg) levels at 1, 3, 6, and 12 months after RFA, with follow-up every 6-12 months thereafter. Any complications were documented during the follow-up period. Recurrence-free survival (RFS) rates were assessed using Kaplan-Meier estimates. Long-term outcomes were evaluated in patients with follow-up of at least 10 years.

RESULTS: The follow-up period ranged from 7 to 180 months (median 133 months). The RFS rates for the 39 patients at 3, 5, and 10 years were 86.8%, 75.5%, and 60.6%, respectively. Among the 24 patients with 37 recurrent PTCs followed for more than 10 years, the volume reduction rate was 99.9% (range 96%-100%), and the complete tumor disappearance rate was 91.9%. The mean serum Tg level also decreased significantly, from 2.66 ± 86.5 mIU/L before ablation to 0.43 ± 0.73 mIU/L (P < 0.001) at the final follow-up. In 14 (58.3%) of the 24 patients, Tg levels were undetectable (below 0.08 mIU/L) at the last follow-up. No life-threatening or delayed complications were observed during the 10-year follow-up period.

CONCLUSION: The high RFS throughout the follow-up period, with efficacy and safety lasting beyond 10 years, supports US-guided RFA as a valuable option for local control of recurrent PTCs.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Chung SR, Baek JH, Choi YJ, et al. Ten-Year Outcomes of Radiofrequency Ablation for Locally Recurrent Papillary Thyroid Cancer. Korean J Radiol. 2024. PMID: 39197830. doi:10.3348/kjr.2024.0208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。